Exhibit 16.1
February 28, 2012
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated February 28, 2012, of Jazz Pharmaceuticals Public Limited Company and are in agreement with the statements contained in the third paragraph on page 1 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP